Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


APA Takeaways: Former Sanofi Exec Reflects On DSM-5, Eroom’s Law And More

Executive Summary

The recent American Psychiatric Association annual meeting featured a lecture on drug development by Sanofi’s former head of CNS development Robert Lenox. In a post-meeting interview, he weighs in on the highs and lows of psychiatric drug development, as well as the newly released fifth edition of the Diagnostic and Statistical Manual of Mental Disorders.

You may also be interested in...

ACA Perspectives: Alkermes Looks For Boon From Expanded Mental Health Benefits

Alkermes’ focus on mental illnesses, substance abuse and other CNS disorders could gain a boost from essential health benefit and mental health parity provisions of the law.

APA Update: New Antidepressants Elbow Into Crowded Market

Lundbeck/Takeda unveil pivotal trial data for Brintellix (vortioxetine) in major depression, while Forest pooled analyses shed more light on levomilnacipran in subgroups. Docs don’t think the new drugs are differentiated, but since antidepressant response is so quirky, the prescribing door is still open.

Mad Scientists And Skunkworks Could Bring Back CNS Creativity, TAP Panelists Say

“Everything that applies to pharma in general is magnified in neuroscience because the timelines are compressed and the punishment for failure is greater,” industry consultant Harry Tracy said at the Therapeutic Area Partnerships meeting.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts